UBS Group AG Ends Substantial Shareholding in StarPharma Holdings Limited as of July 2026

Overview of StarPharma Holdings and Its Market Standing

StarPharma Holdings Limited, trading on the Australian Securities Exchange under ticker SPL, is an Australian biopharmaceutical company focused on pharmaceutical product research, development, and commercialisation. As an ASX-listed entity, StarPharma adheres to continuous disclosure requirements and shareholder reporting obligations, providing transparency regarding major institutional movements in its shareholding structure.

The company’s market position is closely monitored by global institutional investors. The recent exit of UBS Group AG, a major international financial institution, from substantial shareholder status underscores the fluidity of share ownership among listed pharmaceutical companies. Changes in StarPharma’s shareholder register may reflect shifts in investor sentiment, portfolio rebalancing, or evolving investment strategies aligned with the company’s strategic direction and market performance.

UBS Group AG's Shareholding Reduction Over Three Trading Days

Per the Form 605 notice, UBS Securities Australia Ltd, acting on behalf of UBS Group AG and related entities, executed a significant volume of transactions in StarPharma ordinary shares from 22 to 24 June 2026. These included both purchases and sales, with detailed transaction data provided in the appendix. On 22 June, UBS Securities Australia Ltd engaged in numerous buy and sell trades, a pattern that continued on 23 and 24 June.

Appendix A to the Form 605 lists approximately 25 separate transactions on 22 June alone. Further buy and sell orders occurred on 23 and 24 June 2026. This three-day trading window was critical in reducing UBS Group AG’s relevant interest below the substantial holding threshold, prompting the cessation of its substantial shareholder status. The appendix details the net shares sold and the corresponding reduction in voting power.

Regulatory Context: Form 605 and Substantial Shareholder Reporting

The Form 605 is a mandatory regulatory notice under Section 671B of the Corporations Law, required when a shareholder ceases to hold a substantial interest in a listed company. In Australia, a substantial shareholder is defined as one holding five percent or more of voting securities. Falling below this threshold triggers the obligation to lodge a Form 605 notice with the company, outlining all relevant interest changes since the last substantial holding notice.

StarPharma received the previous substantial holding notice from UBS Group AG on 23 June 2026, dated 19 June 2026, confirming UBS’s substantial holding at that time. The transition to non-substantial status occurred by 17 July 2026, with the Form 605 notice filed on 21 July 2026. This regulatory process ensures transparency and informs investors about significant shifts in ownership within listed companies. The detailed transaction records in Appendix A provide a full audit trail of the shareholding change.

Transaction Breakdown: Buy and Sell Orders During Trading Period

The appendix reveals UBS Securities Australia Ltd’s active trading in both buying and selling shares over the three days. Transactions specify share quantities and consideration amounts, reflecting market prices. For example, on 22 June 2026, the initial recorded transaction was a sale of 280 ordinary shares for $401, followed by a larger sale of 108,117 shares for $156,555 the same day. The variation in trade sizes suggests execution of different order magnitudes, potentially for portfolio rebalancing or client mandates.

Subsequent trades on 22 June included purchases such as 55,889 shares valued at $80,128, alongside additional sales and purchases. This pattern indicates a strategic approach to reducing the shareholding while maintaining market liquidity and price stability. The final transaction on 24 June involved 10,771 shares. Collectively, these trades lowered UBS Group AG’s relevant interest below the five percent threshold, necessitating the Form 605 filing.

Authorized Signatories and Compliance Assurance for Form 605

The Form 605 notice was signed by two authorized signatories representing UBS Group AG: Dominic Eichrodt and Ruby Ko, both signing on 21 July 2026. This dual signature protocol ensures compliance with internal authorization standards for significant regulatory disclosures. Ruby Ko is listed as the primary contact, with details provided for follow-up, reflecting UBS’s compliance and administrative framework.

This formal filing process guarantees that the shareholding change information submitted to StarPharma and the market is accurate, authorized, and in line with continuous disclosure obligations under Australian securities law.

Timeline of Shareholding Cessation and Disclosure

The timeline shows that UBS Group AG’s substantial holding notice dated 19 June 2026 was provided to StarPharma on 23 June 2026, confirming substantial interest at that point. Trading activity from 22 to 24 June 2026 then reduced the holding below the threshold. The official cessation date is recorded as 17 July 2026, with the Form 605 notice lodged on 21 July 2026.

This sequence illustrates the regulatory timeline between transaction execution and formal cessation notification, ensuring compliance with Corporations Law requirements for timely disclosure of material shareholding changes. The Form 605 confirms UBS Group AG no longer holds five percent or more of StarPharma’s ordinary shares, signaling a material shift in major shareholders.

Impact on StarPharma’s Shareholder Composition and Investor Considerations

UBS Group AG’s exit from substantial shareholder status represents a key change in StarPharma Holdings Limited’s shareholder base. As a prominent global financial institution, UBS’s stake likely influenced company strategy and voting outcomes. The withdrawal may reflect UBS’s portfolio strategy adjustments, market outlook changes, or completion of a fund mandate involving StarPharma shares. The orderly nature of the transaction record suggests a planned exit rather than distressed selling.

Remaining and prospective investors should consider this shareholder shift in the context of StarPharma’s business fundamentals and sector outlook. The departure of a sophisticated institutional investor could signal changing market perceptions or create opportunities for others to acquire shares. The Form 605 is a factual disclosure without management commentary on transaction rationale or future company strategy.

Continuous Disclosure and Regulatory Compliance Obligations

As an ASX-listed entity, StarPharma Holdings Limited is subject to continuous disclosure rules under the Corporations Law and ASX Listing Rules, requiring immediate announcement of material information affecting security prices. While the Form 605 is filed by UBS Group AG, StarPharma must be notified and assess if further public disclosure is warranted. The cessation of a substantial holding is generally deemed material and subject to disclosure.

This regulatory framework promotes market integrity by ensuring investors receive timely, consistent information on significant ownership changes. Substantial holding notices are publicly available and form part of the company’s disclosure record. StarPharma would have received formal notification of UBS’s status change and may issue announcements as required by ASX rules.

Market Dynamics Behind Institutional Share Trading and Portfolio Adjustments

UBS Securities Australia Ltd’s trading activity from 22 to 24 June 2026 reflects typical institutional portfolio management practices, including position adjustments, client mandate execution, and strategic asset allocation. The phased execution of multiple smaller transactions rather than a single block trade indicates a deliberate approach to manage market impact and liquidity.

The biopharmaceutical sector, where StarPharma operates, faces various factors influencing investor sentiment, such as clinical trial outcomes, regulatory developments, patent status, healthcare policy changes, and competitive pressures. UBS’s reduction below the substantial holding threshold may relate to broader portfolio considerations rather than company-specific events. Without direct commentary from UBS or StarPharma, the precise motivations remain speculative based on the regulatory filing alone.